81 FR 15314 - National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health Federal Register Volume 81, Issue 55 (March 22, 2016)
National Institutes of Health
Federal Register Volume 81, Issue 55 (March 22, 2016)
| Page Range | 15314-15314 | |
| FR Document | 2016-06336 |
[Federal Register Volume 81, Number 55 (Tuesday, March 22, 2016)] [Notices] [Page 15314] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2016-06336] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board of Scientific Counselors, NIDDK. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, NIDDK Date: April 14-15, 2016. Open: April 14, 2016, 8:00 a.m. to 8:15 a.m. Agenda: Introductions and Overview. Place: National Institutes of Health, Porter Neuroscience Research Center, Building 35A Convent Drive, Rooms 620/630, Bethesda, MD 20892. Close: April 14, 2016, 8:15 a.m. to 4:40 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, Porter Neuroscience Research Center, Building 35A Convent Drive, Rooms 620/630, Bethesda, MD 20892. Close: April 15, 2016, 8:00 a.m. to 4:30 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, Porter Neuroscience Research Center, Building 35A Convent Drive, Rooms 620/630, Bethesda, MD 20892. Contact Person: Michael W. Krause, Ph.D., Scientific Director, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Building 5, Room B104, Bethesda, MD 20892-1818, (301) 402-4633, [email protected]. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: March 15, 2016. David Clary, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016-06336 Filed 3-21-16; 8:45 am] BILLING CODE 4140-01-P
![15314 Federal Register / Vol. 81, No. 55 / Tuesday, March 22, 2016 / Notices
exclusively in-licensed check point granted unless within fifteen (15) days Place: National Institutes of Health, Porter
inhibitor with Ad-Her2 and ME–TARP from the date of this published notice, Neuroscience Research Center, Building 35A
vaccine within the Licensed Patent the NIH receives written evidence and Convent Drive, Rooms 620/630, Bethesda,
MD 20892.
Rights. argument that establishes that the grant
Close: April 14, 2016, 8:15 a.m. to 4:40
DATES: Only written comments and/or of the license would not be consistent p.m.
applications for a license which are with the requirements of 35 U.S.C. 209 Agenda: To review and evaluate personal
received by the NIH Office of and 37 CFR part 404.7. qualifications and performance, and
Technology Transfer on or before April Applications for a license in the field competence of individual investigators.
6, 2016 will be considered. of use filed in response to this notice Place: National Institutes of Health, Porter
will be treated as objections to the grant Neuroscience Research Center, Building 35A
ADDRESSES: Requests for copies of the Convent Drive, Rooms 620/630, Bethesda,
patent application, inquiries, and of the contemplated exclusive license.
Comments and objections submitted to MD 20892.
comments relating to the contemplated Close: April 15, 2016, 8:00 a.m. to 4:30
exclusive license should be directed to: this notice will not be made available p.m.
Sabarni K. Chatterjee, Ph.D., M.B.A. for public inspection and, to the extent Agenda: To review and evaluate personal
Senior Licensing and Patenting permitted by law, will not be released qualifications and performance, and
Manager, NCI Technology Transfer under the Freedom of Information Act, competence of individual investigators.
Center, 9609 Medical Center Drive, RM 5 U.S.C. 552. Place: National Institutes of Health, Porter
Neuroscience Research Center, Building 35A
1E530 MSC 9702, Bethesda, MD 20892– Dated: March 16, 2016.
Convent Drive, Rooms 620/630, Bethesda,
9702 (for business mail), Rockville, MD Richard U. Rodriguez, MD 20892.
20850–9702 Telephone: (240)–276– Associate Director, Technology Transfer Contact Person: Michael W. Krause, Ph.D.,
5530; Facsimile: (240)–276–5504E-mail: Center, National Cancer Institute. Scientific Director, National Institute of
chatterjeesa@mail.nih.gov. [FR Doc. 2016–06374 Filed 3–21–16; 8:45 am] Diabetes and Digestive and Kidney Diseases,
SUPPLEMENTARY INFORMATION: This BILLING CODE 4140–01–P
National Institute of Health, Building 5,
invention concerns the identification of Room B104, Bethesda, MD 20892–1818, (301)
402–4633, mwkrause@helix.nih.gov.
immunogenic peptides within TARP,
and their use to create an anti-cancer DEPARTMENT OF HEALTH AND In the interest of security, NIH has
HUMAN SERVICES instituted stringent procedures for entrance
immune response in patients. By onto the NIH campus. All visitor vehicles,
introducing these peptides into a including taxicabs, hotel, and airport shuttles
patient, an immune response against National Institutes of Health
will be inspected before being allowed on
these cancer cells can be initiated by the campus. Visitors will be asked to show one
National Institute of Diabetes and
peptides, resulting in treatment of the form of identification (for example, a
Digestive and Kidney Diseases; Notice government-issued photo ID, driver’s license,
cancer. A phase I clinical trial in stage
of Meeting or passport) and to state the purpose of their
D0 prostate cancer patients is nearing
completion. Initial results indicate a Pursuant to section 10(d) of the visit.
statistically significant decrease in the Federal Advisory Committee Act, as (Catalogue of Federal Domestic Assistance
slope of PSA for 48 weeks after amended (5 U.S.C. App.), notice is Program Nos. 93.847, Diabetes,
vaccination. Endocrinology and Metabolic Research;
hereby given of a meeting of the Board
93.848, Digestive Diseases and Nutrition
Additionally, a novel vaccine of Scientific Counselors, NIDDK. Research; 93.849, Kidney Diseases, Urology
candidate using recombinant The meeting will be open to the and Hematology Research, National Institutes
adenoviruses expressing the public as indicated below, with of Health, HHS)
extracellular (EC) and transmembrane attendance limited to space available.
Dated: March 15, 2016.
(TM) domains of human HER2 Individuals who plan to attend and
(HER2ECTM) are also being developed need special assistance, such as sign David Clary,
that is within the scope of the field of language interpretation or other Program Analyst, Office of Federal Advisory
use licensed to Midissia. The reasonable accommodations, should Committee Policy.
recombinant adenovirus expresses a notify the Contact Person listed below [FR Doc. 2016–06336 Filed 3–21–16; 8:45 am]
chimeric fiber protein having the in advance of the meeting. BILLING CODE 4140–01–P
adenovirus type 35 (Ad5) shaft and The meeting will be closed to the
knob domains, which facilitates public as indicated below in accordance
transduction of human dendritic cells with the provisions set forth in section DEPARTMENT OF HEALTH AND
by the recombinant HER2ECTM 552b(c)(6), Title 5 U.S.C., as amended HUMAN SERVICES
expressing adenovirus. The vaccine for the review, discussion, and
evaluation of individual intramural National Institutes of Health
candidate, namely, AdHer2ECTM) can
potentially to treat patients with Her2 programs and projects conducted by the Submission for OMB Review; 30-day
expressing tumors. Clinical studies with NATIONAL INSTITUTE OF DIABETES Comment Request: Cancer Genomics
this adenovirus based vaccine is AND DIGESTIVE AND KIDNEY Cloud Pilots Survey (NCI)
currently being planned. DISEASES, including consideration of
Both technologies have the potential personnel qualifications and SUMMARY: Under the provisions of
of being developed into a vaccine for performance, and the competence of Section 3507(a)(1)(D) of the Paperwork
several cancer indications or for the Reduction Act of 1995, the National
asabaliauskas on DSK3SPTVN1PROD with NOTICES
individual investigators, the disclosure
treatment of any cancer associated with of which would constitute a clearly Cancer Institute (NCI), the National
increased or preferential expression of unwarranted invasion of personal Institutes of Health, has submitted to the
TARP and Her 2/neu. privacy. Office of Management and Budget
The prospective exclusive license will Name of Committee: Board of Scientific
(OMB) a request for review and
be royalty bearing and will comply with Counselors, NIDDK approval of the information collection
the terms and conditions of 35 U.S.C. Date: April 14–15, 2016. listed below. This proposed information
209 and 37 CFR part 404.7. The Open: April 14, 2016, 8:00 a.m. to 8:15 a.m. collection was previously published in
prospective exclusive license may be Agenda: Introductions and Overview. the Federal Register on January 13,
VerDate Sep<11>2014 17:34 Mar 21, 2016 Jkt 238001 PO 00000 Frm 00095 Fmt 4703 Sfmt 4703 E:\FR\FM\22MRN1.SGM 22MRN1](https://thefederalregister.org/doc/81_FR_15369/page/1.svg)
Document Created: 2018-02-02 15:15:57
Document Modified: 2018-02-02 15:15:57
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Dates | April 14-15, 2016. | |
| FR Citation | 81 FR 15314 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR